Identity
Cerebrolysin is a peptide preparation evaluated as an adjunct in neurological treatment studies.
Selected study only; not a complete clinical review.
Peptide library
Cerebrolysin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The large CASTA trial did not meet its primary combined functional endpoint. Post hoc severe-stroke findings are hypothesis-generating. A complex peptide mixture also requires a matched manufactured preparation.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
1,070 acute ischemic-stroke patients in the randomized CASTA trial.
What the sources found
The primary combined functional endpoint was not significantly improved. Favorable severe-stroke subgroup findings were post hoc and require confirmation.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Cerebrolysin is a peptide preparation evaluated as an adjunct in neurological treatment studies.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- A neutral efficacy result does not establish safety; comprehensive adverse-event assessment remains necessary.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The primary combined functional endpoint was not significantly improved. Favorable severe-stroke subgroup findings were post hoc and require confirmation.
Selected study only; not a complete clinical review.
Adverseeffects
A neutral efficacy result does not establish safety; comprehensive adverse-event assessment remains necessary.
Selected study only; not a complete clinical review.
References
Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. 2012.
PMID: 22282884
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.